Calidi Biotherapeutics Presents New Data on CLD-501, Its In Situ T-Cell Engager Candidate Targeting TROP-2 at the T-Cell Engager Therapeutic Summit
Findings highlight RedTail’s potential to overcome historical limitations of T-cell engagers in solid tumors through tumor-specific, localized expression Findings highlight RedTail’s potential to overcome historical limitations of T-cell engagers in solid tumors through tumor-specific, localized expression
Findings highlight RedTail’s potential to overcome historical limitations of T-cell engagers in solid tumors through tumor-specific, localized expression Findings highlight RedTail’s potential to overcome historical limitations of T-cell engagers in solid tumors through tumor-specific, localized expression
Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.